Sign up to save your podcasts
Or
Share #36 Can Shoreline Biosciences change the future of cell therapy through pluripotent stem cells?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
#36 Can Shoreline Biosciences change the future of cell therapy through pluripotent stem cells?
This episode of BioTech IQ features Kleanthis Xanthopoulos, Ph.D. He is the co-founder, chairman of the board, and CEO of Shoreline Biosciences. As part of our "What's Ahead in Biotech: #2022" series Kleanthis talks about the power of induced pluripotent stem cells (iPSC) derived NK cells, and macrophage immunotherapies. What is the future of immunotherapies? Listen and find out!
https://shorelinebio.com/
https://thebiotechiqpodcast.com/
Check me out on LinkedIn https://www.linkedin.com/in/ammonr/
View all episodes
By Ammon RiveraThis episode of BioTech IQ features Kleanthis Xanthopoulos, Ph.D. He is the co-founder, chairman of the board, and CEO of Shoreline Biosciences. As part of our "What's Ahead in Biotech: #2022" series Kleanthis talks about the power of induced pluripotent stem cells (iPSC) derived NK cells, and macrophage immunotherapies. What is the future of immunotherapies? Listen and find out!
https://shorelinebio.com/
https://thebiotechiqpodcast.com/
Check me out on LinkedIn https://www.linkedin.com/in/ammonr/